Cambendazole: new anthelmintic in the therapy of strongyloidiasis. Clinical trial
Rodrigues, L.D.; Martirani, I.; Cabeça, M.; Soares, W.; Brandão, J.A.
Revista do Instituto de Medicina Tropical de Sao Paulo 19(1): 57-67
1977
ISSN/ISBN: 0036-4665 PMID: 331439 Document Number: 119783
Document emailed within 1 workday
Related Documents
Amato Neto, V.; Moreira, A.A.; Chiaramelli, M.C.; Leme, J.M.; Chiaramelli, D.R.; Campos, R.; Pinto, P.L.; de Sant'ana, E.J.; da Rocha, E.S. 1985: Delimitation of the anthelmintic activity of albendazole. Study concerning human strongyloidiasis Revista do Instituto de Medicina Tropical de Sao Paulo 27(2): 95-98Mikhaĭlitsyn, F.S.; Arkhipov, I.A.; Arkhipova, A.I.; Sevbo, D.P.; Trusov, S.N.; Gitsu, G.A.; Belova, E.E.; Sadov, K.M.; Radionov, A.V. 2012: Preparation of a prototype of the anthelmintic mitranox (MCT-31) and evaluation of its therapeutic efficacy in sheep moniesiosis and strongyloidiasis Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2: 51-52
Mikhaĭlitsyn, F.S.; Sevbo, D.P.; Trusov, S.N.; Arkhipov, I.A.; Belova, E.E.; Sadov, K.M.; Radionov, A.V.; Gitsu, G.A.; Arkhipova, A.I. 2011: Preparation of a prototype of the anthelmintic nadinate (MCT-02) and evaluation of its therapeutic efficacy in sheep moniesiosis and strongyloidiasis Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2: 41-42
Hu, D.; Xu, Z. 1997: Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy Chinese Medical Journal 110(11): 839-842
Baker, N.F.; Walters, G.T.; Hjerpe, C.A.; Fisk, R.A. 1972: Experimental therapy of Dictyocaulus viviparus infection in cattle with cambendazole American Journal of Veterinary Research 33(6): 1127-1130
Hanck, C.; Holzer, B.R. 1992: Strongyloidiasis under immunosuppressive therapy Schweizerische Medizinische Wochenschrift 122(23): 899-902
Spinner, D.; Walter, J.; Vazquez-Gragg, M.; Bloise, T.; Stafford-Smith, M.; Faulkner, E.; Taekman, J. 2011: Php74 Clinical Trial Learning Curves Affect Outcomes Measurement, Patient Safety and Trial Success: Contributing Factors and a Potential Solution in Clinical Trial Simulation Value in Health 14(3): A24-A25
Presson, B.L.; Yazwinski, T.A.; Greenway, T.; Pote, L.; Newby, T. 1984: Controlled field trial on the anthelmintic effectiveness of the morantel sustained-release bolus in grazing calves American Journal of Veterinary Research 45(12): 2628-2630
Yamori, S.; Yamamoto, M.; Kawabata, A.; Nakashima, K.; Iinuma, Y.; Satake, T.; Shimokata, K. 1989: Strongyloidiasis following long-term corticosteroid therapy Nihon Kyobu Shikkan Gakkai Zasshi 27(10): 1226-1230
Kerestély, J.; Fazakas, B.; Grecu, G. 1977: Clinical study of strongyloidiasis Revista de Igiena Bacteriologie Virusologie Parazitologie Epidemiologie Pneumoftiziologie. Bacteriologia Virusologia Parazitologia Epidemiologia 22(2): 81-85
Testa, M.A. 1987: Interpreting quality-of-life clinical trial data for use in the clinical practice of antihypertensive therapy Journal of Hypertension. Suppl: Official Journal of the International Society of Hypertension 5(1): S9-13
Polozok, E.S.; Tokmalaev, A.K. 1978: Clinical aspects and diagnosis of strongyloidiasis Sovetskaia Meditsina 5: 128-132
Tsai, H-Chin.; Lee, S.S.; Liu, Y-Ching.; Lin, W-Ru.; Huang, C-Kai.; Chen, Y-Shen.; Wann, S-Ren.; Tsai, T-Hung.; Lin, H-Hsun.; Yen, M-Yong.; Yen, C-Min.; Chen, E-Rin. 2002: Clinical manifestations of strongyloidiasis in southern Taiwan Journal of Microbiology Immunology and Infection 35(1): 29-36
Tikhomirova, E.P.; Prokhorov, A.F. 1980: Allergic syndrome in the clinical picture of strongyloidiasis Meditsinskaia Parazitologiia i Parazitarnye Bolezni 49(5): 16-21
Reddy, I.S.; Swarnalata, G. 2005: Fatal disseminated strongyloidiasis in patients on immunosuppressive therapy: report of two cases Indian Journal of Dermatology Venereology and Leprology 71(1): 38-40
Mikhaĭlitsyn, F.S.; Drusviatskaia, S.K.; Uvarova, N.A.; Taits, S.Z.; Stoianovich, F.M.; Vol'kenshteĭn, I.B.; Lebedeva, M.N.; Krotov, A.I.; Lychko, N.D. 1994: The technology for manufacturing antiparasitic preparations. 3. the development of a technology for producing the anthelmintic embovin (pyrantel embonate) in finely dispersed form and the evaluation of its anthelmintic properties Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2: 24-26
Oliver, N.W.; Rowbottom, D.J.; Sexton, P.; Goldsmid, J.M.; Byard, R.; Tooth, M.; Thomson, K.S. 1989: Chronic strongyloidiasis in Tasmanian veterans--clinical diagnosis by the use of a screening index Australian and New Zealand Journal of Medicine 19(5): 458-462
Federico, M.; Clò, V.; Carella, A.M. 1996: High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial Leukemia 10 Suppl. 2: S69-S71
Johansen, S.; Baardsen, A. 1981: Ureteral calculi and fluid therapy. a clinical trial Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 101(3): 211-212
Lavey, R.S. 1998: Clinical trial experience using erythropoietin during radiation therapy Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 174(Suppl 4): 24-30